Colchicine for the treatment of COVID‐19 – Mikolajewska, A – 2021 | Cochrane Library

Collapse all Expand all Background The development of severe coronavirus disease 2019 (COVID‐19) and poor clinical outcomes are associated with hyperinflammation and a complex dysregulation of the immune response. Colchicine is an anti‐inflammatory medicine and is thought to improve disease outcomes in COVID‐19 through a wide range of anti‐inflammatory mechanisms. Patients and…

Read the full article here

Related Articles